Physician profile
Radha Bernander
NPI 1396273595
$73,636.26
in general payments reported to CMS, 2019-2025
54 companies · $33K in 2025
The $33K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,756 · 2022: $2,935 · 2023: $3,877 · 2024: $31K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Food and Beverage: $11K · Travel and Lodging: $311 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,490.24 |
| Food and Beverage | $11,132.46 |
| Travel and Lodging | $310.88 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $57,440.41 | 2021-2025 | Omnipod, Omnipod |
| Astrazeneca Pharmaceuticals Lp | $2,116.57 | 2021-2024 | Farxiga |
| Mannkind Corporation | $1,845.98 | 2021-2025 | Afrezza |
| Lilly USA, LLC | $1,675.87 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $1,367.69 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $1,318.27 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $768.06 | 2023-2025 | Korlym |
| Abbott Laboratories | $619.74 | 2021-2025 | Freestyle Libre 3 |
| Intuity Medical INC | $589.55 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Abbvie INC. | $435.09 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.84 | 2021-2024 | Jardiance, Synjardy, Trijardy Xr |
| Cequr Corporation | $414.07 | 2021-2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $405.00 | 2021-2025 | |
| Amgen INC. | $393.96 | 2021-2025 | Evenity, Prolia, Tepezza |
| Tandem Diabetes Care, INC. | $362.65 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $344.65 | 2021-2025 | |
| Pfizer INC. | $279.18 | 2021-2025 | |
| Ibsa Pharma INC. | $264.87 | 2021-2024 | Tirosint, Licart, Licart |
| Beta Bionics, INC. | $241.04 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Radius Health, INC. | $237.14 | 2021-2025 | Tymlos |
| Ascendis Pharma Endocrinology INC | $173.22 | 2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $162.86 | 2021-2025 | |
| Sequel Med Tech, LLC | $155.82 | 2025 | Twiist |
| Zealand Pharma US, INC. | $154.70 | 2021-2022 | |
| Medtronic, INC. | $146.20 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $137.38 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $129.89 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $116.26 | 2021-2023 | Steglatro, Steglujan |
| Currax Pharmaceuticals LLC | $109.50 | 2021-2025 | Contrave, Nexletol, Nexlizet |
| Amneal Pharmaceuticals LLC | $63.54 | 2021-2025 | Unithroid |
| Alexion Pharmaceuticals, INC. | $61.51 | 2022-2023 | Strensiq |
| Amarin Pharma, INC. | $60.02 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.33 | 2023-2024 | Cycloset |
| Embecta Corp. | $45.55 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Antares Pharma, INC. | $44.62 | 2024 | Xyosted |
| Tolmar, INC. | $43.25 | 2023-2025 | Jatenzo |
| Kyowa Kirin, INC. | $40.88 | 2024 | Crysvita |
| Madrigal Pharmaceuticals | $40.23 | 2025 | Rezdiffra |
| Esperion Therapeutics, INC. | $33.52 | 2022-2024 | Nexletol |
| Nevro Corp. | $30.55 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $29.35 | 2024 | Crysvita |
| Theracosbio, LLC | $26.62 | 2024 | Brenzavvy |
| Vivus LLC | $26.05 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $24.63 | 2024 | |
| Grt US Holding, INC. | $23.38 | 2021 | |
| Neurocrine Biosciences, INC. | $21.87 | 2025 | |
| Boston Scientific Corporation | $21.39 | 2025 | General - Pain Management |
| Endo Pharmaceuticals INC. | $20.11 | 2021 | |
| Amryt Pharma Holdings Ltd | $19.48 | 2023 | Mycapssa |
| Averitas Pharma INC. | $17.88 | 2025 | Qutenza |
| Acella Pharmaceuticals, LLC | $17.65 | 2025 | NP Thyroid 60 |
| Recordati_rare_diseases_inc. | $16.88 | 2025 | Isturisa |
| Alvogen INC | $16.49 | 2025 | Teriparatide |
| Halozyme INC | $13.02 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radha Bernander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.